Clinical Trials Logo

Lymphocytic Leukemia clinical trials

View clinical trials related to Lymphocytic Leukemia.

Filter by:

NCT ID: NCT05272813 Recruiting - Clinical trials for Small Lymphocytic Lymphoma

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Start date: April 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

NCT ID: NCT05065866 Active, not recruiting - Hodgkin Lymphoma Clinical Trials

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Start date: November 18, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.

NCT ID: NCT03219450 Recruiting - Clinical trials for Lymphocytic Leukemia

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Start date: August 18, 2021
Phase: Phase 1
Study type: Interventional

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: - Personalized NeoAntigen Vaccine - Poly-ICLC - Cyclophosphamide - Pembrolizumab

NCT ID: NCT02885038 Completed - Multiple Myeloma Clinical Trials

Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies

TCP
Start date: January 2015
Phase: N/A
Study type: Observational

Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes. Because of the relative scarcity of PCs the selection of a specific PC for issue to the patient remains a challenging process. Regulatory agencies do not fully address these characteristics in their recommendations for prophylactic transfusions. The aim of the study was to analyse the effect of product-related factors in a real life setting, in order to determine which ones are the most relevant when selecting PCs for patients in prophylactic conditions. Two different endpoints are studied: the corrected count increment and the platelet transfusion time intervals.

NCT ID: NCT02556892 Completed - Clinical trials for Lymphocytic Leukemia

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: July 3, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of Ibrutinib in Japanese participants with treatment-naive chronic lymphocytic leukemia ( CLL) or small lymphocytic lymphoma (SLL).

NCT ID: NCT02481297 Completed - Leukemia Clinical Trials

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Start date: June 23, 2015
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of the drug combination will also be studied.

NCT ID: NCT02434484 Completed - Multiple Myeloma Clinical Trials

Symbenda Post-Marketing Surveillance (PMS)

Start date: July 4, 2018
Phase:
Study type: Observational

This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The main objective is to obtain safety information related to Symbenda treatment from clinical practice.

NCT ID: NCT01499147 Completed - Multiple Myeloma Clinical Trials

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Start date: February 2000
Phase: N/A
Study type: Interventional

New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Recent data have suggested that fludarabine may be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity previously observed with cyclophosphamide/ busulfan regimens.

NCT ID: NCT00935792 Completed - Clinical trials for Lymphocytic Leukemia

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when given together with alemtuzumab and will see how well they work in treating patients with recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).

NCT ID: NCT00609869 Completed - Clinical trials for Mantle Cell Lymphoma

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Revlimid® is a drug that changes the immune system and it may also get in the way with the growth of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug Administration (FDA) for the treatment of specific types of Myelodysplasia syndrome (MDS) and Multiple Myeloma, two different types of blood cancer. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental.